Atrial fibrillation in β-thalassemia Major Patients: Diagnosis, Management and Therapeutic Options

References

• Galanello R, Origa R. β-Thalassemia. Orphanet J Rare Dis. 2010;5:11.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. The β-thalassemias. N Engl J Med. 1999;341(2):99–109.
   PubMed Web of Science ®Google Scholar
• Barbero U, Destefanis P. An Indian-look right into restrictive cardiomyopathies. Indian Heart J. 2015;67(6):512–513.
   PubMedGoogle Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major Ann NY Acad Sci. 1998;850:227–231.
   PubMed Web of Science ®Google Scholar
• Thalassaemia International Federation guidelines for the clinical management of thalassemia. Nicosia (Cyprus): Thalassaemia International Federation, 2008. ISBN-13: 978-9962-623-70-9.
   Google Scholar
• Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Bailliére’s Clin Haematol. 1998;11(1):1–51.
   PubMed Web of Science ®Google Scholar
• Kostopoulou AG, Tsiapras DP, Chaidaroglou AS, et al. The pathophysiological relationship and clinical significance of left atrial function and left ventricular diastolic dysfunction in β-thalassemia major. Am J Hematol. 2014;89(1):13–18.
   PubMed Web of Science ®Google Scholar
• Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011;124(20):2253–2263
   PubMed Web of Science ®Google Scholar
• Barbero U, Destefanis P, Pozzi R, et al. Exercise stress echocardiography with tissue Doppler Imaging (TDI) detects early systolic dysfunction in β-thalassemia major patients without cardiac iron overload. Mediterr J Hematol Infect Dis. 2012;4(1):e2012037.
   PubMedGoogle Scholar
• Barbero U, Longo F Destefanis P, et al. Worsening of myocardial performance index in β-thalassemia patients despite permanently normal iron load at MRI: A simple and cheap index reflecting cardiovascular involvement? IJC Metabolic & Endocrine. 2016;13:41–44.
   Web of Science ®Google Scholar
• Buja LM, Roberts WC. Iron in the heart: Etiology and clinical significance. Am J Med. 1971;51(2):209–221.
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Pannone B, et al. Atrial fibrillation and β thalassemia major: The predictive role of the 12-lead electrocardiogram analysis. Indian Pacing Electrophysiol J. 2014;14(3):121–132.
   PubMedGoogle Scholar
• Rago A, Russo V, Papa AA, et al. The role of the atrial electromechanical delay in predicting atrial fibrillation in β-thalassemia major patients. J Interv Card Electrophysiol. 2017;48(2):147–157.
   PubMed Web of Science ®Google Scholar
• Bell RM, Mohamed S, Ako EA, et al. The prevalence and risk factors for atrial fibrillation in β-thalassemia major: A cross-sectional study in a UK specialist cardio-haematology clinic. European Society of Cardiology Congress, London, UK; 29 August-2 September 2015; Poster session 6: Atrial fibrillation VI. Eur Heart J. 2015;36(1):916.
   Google Scholar
• Coumel P. Cardiac arrhythmias and the autonomic nervous system. J Cardiovasc Electrophysiol. 1993;4(3):338–355.
   PubMed Web of Science ®Google Scholar
• Kuryshev YA, Brittenham GM, Fujioka H, et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes: Implications for the arrhythmogenesis of human siderotic heart disease. Circulation. 1999;100(6):675–683.
   PubMed Web of Science ®Google Scholar
• Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–1968.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Udelson JE, Arai AE, et al. American heart association committee on heart failure and transplantation of the council on clinical cardiology and council on cardiovascular radiology and imaging. Cardiovascular function and treatment in β-thalassemia major: A consensus statement from the American Heart Association. Circulation. 2013;128(3):281–308.
   PubMed Web of Science ®Google Scholar
• Ozdogan O, Alp A, Turker M, Atabey B. Determination of early cardiac deterioration in β-thalassaemia major by echocardiography. Acta Cardiol. 2013;68(3):299–305.
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Pannone B, et al. Early electrocardiographic evaluation of atrial fibrillation risk in β-thalassemia major patients. Int J Hematol. 2011;93(4):446–451.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: A multicenter study. Blood. 2001;97(11):3411–3416.
   PubMed Web of Science ®Google Scholar
• Franzoni F, Galeta F, Di Muro C, et al. Heart rate variability and ventricular late potentials in β thalassemia major. Haematologica. 2004;89(2):233–234.
   PubMed Web of Science ®Google Scholar
• Gurses D, Ulger Z, Levent E, et al. Time domain heart rate variability analysis in patients with thalassaemia major. Acta Cardiologica. 2005;60(5):477–482.
   PubMed Web of Science ®Google Scholar
• Amoozgar H, Zeighami S, Haghpanah S, Karimi M. A comparison of heart function and arrhythmia in clinically asymptomatic patients with β thalassemia intermedia and β thalassemia major. Hematology. 2017;22(1):25–29.
   PubMed Web of Science ®Google Scholar
• Yetimakman AF, Oztarhan K, Aydogan G. Comparison of tissue Doppler imaging with MRI t2* and 24-hour rhythm holter heart rate variability for diagnosing early cardiac impairment in thalassemia major patients. Pediatr Hematol Oncol. 2014;31(7):597–606.
   PubMed Web of Science ®Google Scholar
• Kolios M, Korantzopoulos P, Vlahos AP, et al. Electrocardiographic abnormalities and arrhythmic risk markers in adult patients with β thalassemia major. Int J Cardiol. 2016;15(221):932–936.
   Web of Science ®Google Scholar
• Prystowsky EN, Padanilam BJ, Fogel RI. Treatment of atrial fibrillation. JAMA. 2015;314(3):278–288.
   PubMed Web of Science ®Google Scholar
• Russo V, Papa AA, Rago A, Nigro G. Atrial fibrillation in β thalassemia major: How to perform effective screening and early detection. Hematology. 2017;22(6):368–369.
   PubMed Web of Science ®Google Scholar
• ADTL, Regione Lombardia. Linee guida per la prevenzione e il trattamento delle complicanze della talassemia. 1999;1(1):1–21 (https://www.google.com/url?sa=f&rct=j&q=s&source=web&cd-0ahUKEwidz7D4MbbAhWMuxQKHXUrCckQFggolv3A%2F%2Fwww.osservatoriomalattierare.it%2Fdocumenti%2Fcategory%2F2-linee-guida-sule-malattie-rare%3Fdownload%3D122£Alinee-guida-talassemia-2010&usg=AOvVaw3t2Njg81BAizkaBADzRz-Y).
   Google Scholar
• Fondazione L. Giambrone, Linee guida per le complicanze cardiache nella talassemia major. Primo aggiornamento. 2008;1(1):7–24 (http://www.fondazionegiambrone.it/wp-content/uploads/2012/05/Linee_guida_per_le_complicanze_cardiache.pdf).
   Google Scholar
• Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364(2):146–156.
   PubMed Web of Science ®Google Scholar
• Vassilopoulou S, Anagnostou E, Paraskevas G, Spengos K. Etiology and treatment of ischaemic stroke in patients with β-thalassemia major. Eur J Neurol. 2011;18(12):1426–1428.
   PubMed Web of Science ®Google Scholar
• Taher A, Mehio G, Isma'eel H, Cappellini MD. Stroke in thalassemia: A dilemma. Am J Hematol. 2008;83(4):343.
   PubMed Web of Science ®Google Scholar
• Auger D, Pennell DJ. Cardiac complications in thalassemia major. Ann NY Acad Sci. 2016;1368(1):56–64.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–1678.
   PubMed Web of Science ®Google Scholar
• Apostolou C, Klonizakis P, Mainou M, et al. Rivaroxaban use in patients with hemoglobinopathies. Hemoglobin. 2017;41(3):223–224.
   PubMed Web of Science ®Google Scholar
• Wynn GJ, Das M, Bonnett LJ, et al. Efficacy of catheter ablation for persistent atrial fibrillation: A systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ Arrhythm Electrophysiol. 2014;7(5):841–852.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Yamashita S, Suzuki M, et al. Efficacy of catheter ablation of focal sources in persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2018;29(4):559–565.
   PubMed Web of Science ®Google Scholar
• Anselmino M, Ferraris F, Cerrato N, et al. Left persistent superior vena cava and paroxysmal atrial fibrillation: The role of selective radio-frequency transcatheter ablation. J Cardiovasc Med (Hagerstown). 2014;15(8):647–652.
   PubMed Web of Science ®Google Scholar
• Gaita F, Scaglione M, Battaglia A, et al. Very long-term outcome following transcatheter ablation of atrial fibrillation. Are results maintained after 10 years of follow up? Europace. 2018;20(3):443–450.
   PubMed Web of Science ®Google Scholar